首頁 > 市場調查報告書 > 醫療設備

生物材料

市場調查報告書

商品編碼

1373366

全球神經修復與再生市場 - 2023-2030

Global Nerve Repair and Regeneration Market - 2023-2030

出版日期: 2023年10月18日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

神經修復是組織工程的一個領域，旨在移植可以模仿細胞外基質並增強神經再生的人工神經。神經修復和再生手術旨在恢復因神經損傷而部分或完全喪失的功能和感覺。

神經導管和包裹物為週邊神經損傷提供了包裹並保護神經環境。常用的神經修復手術包括幹細胞治療、直接神經修復和神經移植。

市場動態

增加對神經刺激系統的投資

神經刺激設備在診斷和管理神經系統疾病方面發揮著至關重要的作用，它使外科醫生能夠為患者提供更有針對性和更有效的護理。重點公司的主要投資有助於推動市場成長，這些公司的有效資金有助於將研究發現轉化為神經系統疾病的新診斷和治療方法。

例如，2023 年 4 月，Saluda Medical Inc. 宣布完成由新投資者 Wellington Management 領投的 1.5 億美元股權融資。融資淨收益將用於推進 Evoke 脊髓模擬（SCS）系統的商業發布。

此外，2022 年 2 月，Nalu Medical 透過股權融資籌集了 1.04 億美元。此輪融資由新投資者 MVM Partners 和 Gilde Healthcare 領投，Pura Vida Investments 參與投資 Nalu 神經刺激系統，該系統已獲得 FDA 批准用於脊髓刺激 (SCS) 和周圍神經刺激 (PNS) 適應症。

此外，2021年10月，SPR Therapeutics 透過超額認購的 D 系列成長股權融資籌集了 3,700 萬美元，以加速其經 FDA 批准的 SPRINT 週邊神經刺激系統的快速成長的商業應用。

此外，全球神經修復和再生市場受到多種因素的推動，例如神經損傷和神經系統疾病盛行率的上升、技術進步以及微創手術的增加預計將在預測期內推動市場。

神經刺激費用高

神經科設備的高成本、政府機構的嚴格監管以及神經科刺激設備的合規標準是預計市場在預測期內受到阻礙的因素。例如，在美國，深部腦部刺激手術的費用（包括植入設備、住院費和麻醉費）從 35,000 美元到 100,000 美元不等。

Neurostimulation devices play a crucial role in diagnosing and managing neurological conditions by allowing surgeons to provide more targeted and effective care to patients. The major investments from key companies help to drive market growth and these effective funds from companies help to transform research discoveries into new diagnoses and treatments for neurological diseases.

For instance, in April 2023, Saluda Medical Inc. declared the raise of a $150 million equity financing round led by new investor Wellington Management. The net proceeds from the financing are used to advance the commercial release of the Evoke Spinal Cord Simulation (SCS) System.

Additionally, in February 2022, Nalu Medical raised $104M in Equity Financing. The round was led by new investors MVM Partners and Gilde Healthcare with participation from Pura Vida Investments for the Nalu Neurostimulation System which is FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications.

Also, in October 2021, SPR Therapeutics raised $37 million in oversubscribed Series D growth equity financing to accelerate the rapidly growing commercial uptake of its FDA-cleared SPRINT Peripheral Nerve Stimulation System.

Furthermore, the global nerve repair and regeneration market is driven by various factors like the rising prevalence of nerve injuries and neurological diseases, technological advancements, and a rise in minimally invasive surgeries are expected to drive the market in the forecast period.

The high cost of nerve stimulation

The high cost of neurology devices, strict regulations by the government bodies, and compliance standards of the neurology stimulation devices are the factors the market is expected to get hampered in the forecast period. For instance, in the United States, the cost of deep brain stimulation surgery including the implanted device, hospital fees, and anesthesia can range from $35,000 to $100,000.

Segment Analysis

The global nerve repair and regeneration market is segmented based on product type, surgery type, end users and region.

Neurostimulation and Neuromodulation Devices accounted for approximately 39.8% of the market share

Neurostimulation devices utilize a battery and electrodes to provide electrical or magnetic forces through the scalp to certain regions of the brain. Neurostimulation and neuromodulation devices are expected to hold the largest market share over the period forecast owing to increasing new standard nerve stimulator launches and technological advancements.

For instance, in January 2023, Abbott Laboratories launched the world's smallest implantable, rechargeable spinal cord stimulation system for chronic pain. This stimulation system is clinically proven to reduce pain and improve people's ability to perform everyday activities.

Additionally, in February 2023, LivaNova launched SenTiva Duo, an implantable pulse generator that provides vagus nerve stimulation therapy for patients with drug-resistant epilepsy.

Geographical Analysis

North America is expected to hold a significant position in the global nerve repair and regeneration market share

The global nerve repair and regeneration market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of neurological disorders, and product launches, this trend is anticipated to continue throughout the forecast period.

For instance, an estimated 6.7 million Americans aged 65 and over are predicted to have Alzheimer's dementia in 2023, and this number may increase to 13.8 million by 2060, according to a report released by the Alzheimer's Association in March 2022. Hence, the usage of nerve stimulation devices increases in treating Alzheimer's patients.

Additionally, in September 2023, launched its Axoguard HA+ Nerve Protector. It is a revolutionary peripheral nerve injury protection device that is specially crafted to offer both short- and long-term protection.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global nerve repair and regeneration market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the nerve repair and regeneration market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Medtronic Plc., Abbott Laboratories, Boston Scientific Corporation, Cirtec Medical, Synapse Biomedical Inc., Renishaw Plc., Orthomed LLC, AxoGen Inc., Integra LifeSciences LinaNova Plc. Among others.

Key Developments

In February 2023, ANEUVO, initiated a clinical study of the ExaStim TSS system, a wirelessly-controlled neuromodulation system designed to deliver transcutaneous spinal cord stimulation (TSS).
In March 2022 Integra LifeSciences Holding Corporation introduced NeuraGen 3D Nerve Guide Matrix which is a resorbable implant for the repair of peripheral nerve discontinuities.

Why Purchase the Report?

To visualize the global nerve repair and regeneration market segmentation based on product type, surgery type, end users and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of nerve repair and regeneration market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global nerve repair and regeneration market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Surgery Type
3.3. Snippet by End User
3.4. Snippet by Region

4. Market Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing investments in nerve stimulation systems
  - 4.1.1.2.
- 4.1.2. Restraints
  - 4.1.2.1. The high cost of nerve stimulation
  - 4.1.2.2.
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Neurostimulation and Neuromodulation Devices *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Spinal Cord Stimulation Devices
- 7.2.4. Deep Brain Stimulation Devices
- 7.2.5. Sacral Nerve Stimulation Devices
- 7.2.6. Vagus Nerve Stimulation Devices
- 7.2.7. Gastric Electric Stimulation Devices
7.3. Biomaterial
- 7.3.1. Nerve Conduit
- 7.3.2. Nerve Wrap
- 7.3.3. Nerve Graft
- 7.3.4. Others

8. By Surgery Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 8.1.2. Market Attractiveness Index, By Surgery Type
8.2. Stem cell therapy *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Direct Nerve Repair
8.4. Nerve grafting
8.5. Others

9. By End Users

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 9.1.2. Market Attractiveness Index, By End Users
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Neuro Centers
9.4. Ambulatory Surgical Centers
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. Australia
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Medtronic Plc
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Abbott Laboratories
12.3. Boston Scientific Corporation
12.4. Cirtec Medical
12.5. Synapse Biomedical Inc.
12.6. Renishaw Plc.
12.7. Orthomed LLC
12.8. AxoGen Inc
12.9. Integra LifeSciences
12.10. LinaNova Plc.